A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061

• Drug: UK-453,061
  
  Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
• Drug: UK-453,061
  
  Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days

• Experimental: Stage 1
  
  Intervention: Drug: UK-453,061
• Experimental: Stage 2
  
  Intervention: Drug: UK-453,061

Inclusion Criteria:

• Asymptomatic HIV-1 infected male and patients aged 18-55 years inclusive.
• Patients with virus not containing NNRTI resistant mutations as determined by the VircoGEN virtual phenotyping essay.

Exclusion Criteria:

• Patients with a CD4 count less than 250 cells/mm3.
• Patients whose HIV infection has been diagnosed less than 3 months prior to screening, or for whom there is evidence of recent seroconversion.
• Patients with an HIV viral load less than 5000 copies/ml using RT-PCR(Roche Amplicor v1.5).